Regeneron Pharmaceuticals, Inc.
REGN
$527.78
-$19.89-3.63%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -2.68% | 12.04% | 11.85% | 11.45% | -0.59% |
| Total Other Revenue | -29.94% | -15.58% | -17.43% | 50.79% | 0.78% |
| Total Revenue | -3.70% | 10.33% | 10.65% | 12.32% | -0.54% |
| Cost of Revenue | 6.51% | 16.72% | 16.60% | 12.75% | 7.92% |
| Gross Profit | -15.44% | 4.11% | 5.79% | 11.93% | -8.77% |
| SG&A Expenses | -8.13% | 7.39% | 11.54% | 16.38% | 14.62% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | 2,533.33% | -- |
| Total Operating Expenses | 2.26% | 13.91% | 15.12% | 14.57% | 9.81% |
| Operating Income | -21.94% | 1.66% | 2.70% | 7.58% | -22.84% |
| Income Before Tax | 29.16% | -16.51% | 34.41% | 50.35% | -18.33% |
| Income Tax Expenses | 552.11% | 436.67% | 47.96% | 71.00% | -152.99% |
| Earnings from Continuing Operations | 12.01% | -20.86% | 33.02% | 47.90% | -11.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 12.01% | -20.86% | 33.02% | 47.90% | -11.71% |
| EBIT | -21.94% | 1.66% | 2.70% | 7.58% | -22.84% |
| EBITDA | -17.68% | 2.69% | 3.72% | 8.45% | -19.45% |
| EPS Basic | 13.16% | -21.60% | 30.81% | 46.40% | -12.29% |
| Normalized Basic EPS | -14.54% | 6.24% | 4.40% | 11.93% | -15.34% |
| EPS Diluted | 15.95% | -20.81% | 29.81% | 46.00% | -12.55% |
| Normalized Diluted EPS | -12.45% | 7.24% | 3.61% | 11.61% | -15.60% |
| Average Basic Shares Outstanding | -1.02% | 0.94% | 1.69% | 1.03% | 0.65% |
| Average Diluted Shares Outstanding | -3.39% | 0.00% | 2.47% | 1.32% | 0.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |